Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone ED50 for inhibition of TSWL stimulation with propofol in ESWL for pancreatic duct and common bile duct stones
ChiCTR2100052105Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxycodone in Pancreatic duct stone and choledocholithiasis, sponsored by Hangzhou First People's Hospital. Primary endpoint: Body movement response to TSWL stimulation. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
oxycodone
03
Conditions
Pancreatic duct stonecholedocholithiasis
Beyond the preview
Go deeper on ChiCTR2100052105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052105.